Ellipticine Cytotoxicity to Cancer Cell Lines - a Comparative Study

Overview

Journal Interdiscip Toxicol

Specialty Biology

Date 2011 Jul 15

PMID 21753906

Citations 21

Authors

Marie Stiborova

Jitka Poljakova

Eva Martinkova

Lucie Borek-Dohalska

Tomas Eckschlager

Rene Kizek

Eva Frei

Affiliations

Soon will be listed here.

Abstract

Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action. This anticancer agent should be considered a pro-drug, whose pharmacological efficiency and/or genotoxic side effects are dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation to species forming covalent DNA adducts. Ellipticine can also act as an inhibitor or inducer of biotransformation enzymes, thereby modulating its own metabolism leading to its genotoxic and pharmacological effects. Here, a comparison of the toxicity of ellipticine to human breast adenocarcinoma MCF-7 cells, leukemia HL-60 and CCRF-CEM cells, neuroblastoma IMR-32, UKF-NB-3 and UKF-NB-4 cells and U87MG glioblastoma cells and mechanisms of its action to these cells were evaluated. Treatment of all cells tested with ellipticine resulted in inhibition of cell growth and proliferation. This effect was associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by 13-hydroxy- and 12-hydroxyellipticine, the ellipticine metabolites generated by CYP and peroxidase enzymes, in MCF-7, HL-60, CCRF-CEM, UKF-NB-3, UKF-NB-4 and U87MG cells, but not in neuroblastoma UKF-NB-3 cells. Therefore, DNA adduct formation in most cancer cell lines tested in this comparative study might be the predominant cause of their sensitivity to ellipticine treatment, whereas other mechanisms of ellipticine action also contribute to its cytotoxicity to neuroblastoma UKF-NB-3 cells.

Citing Articles

Effects of an indole derivative on cell proliferation, transfection, and alternative splicing in production of lentiviral vectors by transient co-transfection.

Mier N, Roper D PLoS One. 2024; 19(6):e0297817.

PMID: 38833479 PMC: 11149887. DOI: 10.1371/journal.pone.0297817.

New Flavonoid Derivatives from and Their α-Glucosidase Inhibitory and Cytotoxic Activities.

Do L, Sichaem J Molecules. 2022; 27(13).

PMID: 35807266 PMC: 9268484. DOI: 10.3390/molecules27134023.

Discovery of hydrazide-based pyridazino[4,5-]indole scaffold as a new phosphoinositide 3-kinase (PI3K) inhibitor for breast cancer therapy.

Sarhan A, Boraei A, Barakat A, Nafie M RSC Adv. 2022; 10(33):19534-19541.

PMID: 35515454 PMC: 9054070. DOI: 10.1039/d0ra02798g.

Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.

Amewu R, Sakyi P, Osei-Safo D, Addae-Mensah I Molecules. 2021; 26(23).

PMID: 34885716 PMC: 8658833. DOI: 10.3390/molecules26237134.

Paradoxical Pro-angiogenic Effect of Low-Dose Ellipticine Identified by In Silico Drug Repurposing.

Oh J, Lee H, Jeong Y, Yoon S, An H, Baek M Int J Mol Sci. 2021; 22(16).

PMID: 34445773 PMC: 8396501. DOI: 10.3390/ijms22169067.

References

Stiborova M, Rupertova M, Aimova D, Ryslava H, Frei E . Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology. 2007; 236(1-2):50-60. DOI: 10.1016/j.tox.2007.03.026. View

Martinkova E, Maglott A, Leger D, Bonnet D, Stiborova M, Takeda K . alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer. 2010; 127(5):1240-8. DOI: 10.1002/ijc.25187. View

Stiborova M, Rupertova M, Frei E . Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta. 2010; 1814(1):175-85. DOI: 10.1016/j.bbapap.2010.05.016. View

Stiborova M, Breuer A, Aimova D, Stiborova-Rupertova M, Wiessler M, Frei E . DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int J Cancer. 2003; 107(6):885-90. DOI: 10.1002/ijc.11511. View

Froelich-Ammon S, Patchan M, Osheroff N, Thompson R . Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem. 1995; 270(25):14998-5004. DOI: 10.1074/jbc.270.25.14998. View

Martinkova E, Dontenwill M, Frei E, Stiborova M . Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett. 2009; 30 Suppl 1:60-6. View

Stiborova M, Sejbal J, Borek-Dohalska L, Aimova D, Poljakova J, Forsterova K . The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res. 2004; 64(22):8374-80. DOI: 10.1158/0008-5472.CAN-04-2202. View

Auclair C . Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys. 1987; 259(1):1-14. DOI: 10.1016/0003-9861(87)90463-2. View

Stiborova M, Stiborova-Rupertova M, Borek-Dohalska L, Wiessler M, Frei E . Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol. 2003; 16(1):38-47. DOI: 10.1021/tx0200818. View

10.

Kuo P, Hsu Y, Kuo Y, Chang C, Lin C . The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs. 2005; 16(7):789-95. DOI: 10.1097/01.cad.0000171768.36317.93. View

11.

Poljakova J, Frei E, Gomez J, Aimova D, Eckschlager T, Hrabeta J . DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 2007; 252(2):270-9. DOI: 10.1016/j.canlet.2006.12.037. View

12.

Kuo Y, Kuo P, Hsu Y, Cho C, Lin C . Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 2005; 78(22):2550-7. DOI: 10.1016/j.lfs.2005.10.041. View

13.

Garbett N, Graves D . Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents. 2004; 4(2):149-72. DOI: 10.2174/1568011043482070. View

14.

McCormick D, Adamowski C, Fiks A, Moon R . Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res. 1981; 41(5):1690-4. View

15.

Cinatl Jr J, Cinatl J, Driever P, Kotchetkov R, Pouckova P, Kornhuber B . Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs. 1998; 8(10):958-63. DOI: 10.1097/00001813-199711000-00007. View

16.

Stiborova M, Rupertova M, Schmeiser H, Frei E . Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006; 150(1):13-23. DOI: 10.5507/bp.2006.002. View

17.

Kuo P, Hsu Y, Chang C, Lin C . The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 2005; 223(2):293-301. DOI: 10.1016/j.canlet.2004.09.046. View

18.

Singh M, Hill G, Peoch D, Rayner B, Imbach J, Lown J . High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry. 1994; 33(34):10271-85. DOI: 10.1021/bi00200a007. View

19.

Stiborova M, Bieler C, Wiessler M, Frei E . The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 2002; 62(12):1675-84. DOI: 10.1016/s0006-2952(01)00806-1. View

20.

Moserova M, Kotrbova V, Rupertova M, Naiman K, Hudecek J, Hodek P . Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett. 2008; 29(5):728-32. View